HiJAKing Immunotherapy-Resistant Melanoma for a Cure
Abstract
Immune checkpoint blockers (ICBs) have brought great promise to patients with advanced melanoma, a tumor type that was claimed largely incurable not long ago. However, therapeutic resistance to ICBs has limited their utility in the clinic. Here, we provide a commentary on recent research endeavors concerning ICB resistance in melanoma patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 14, 2023
- Source ID
- 10.1093/oncolo/oyac270
Entities
People
- Hongxing Shen
- James A. Bonner
- Lewis Zhichang Shi
- Oluwagbemiga A. Ojo
Organizations
- American Cancer Society
- Cancer Research Institute
- Congressionally Directed Medical Research Programs
- National Institutes of Health
- Siemens Healthineers
- University of Alabama
- University of Alabama at Birmingham
- University of Alabama at Birmingham School of Medicine